JOHNSON & JOHNSON
JOHNSON & JOHNSON (JNJ) Stock News
The latest JNJ headlines and market coverage — 5 recent stories, updated throughout the day.
- Zacks Investment Research·
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
Johnson & Johnson is highlighted as a compelling dividend investment with a 2.02% yield, outperforming both its industry (1.93%) and the S&P 500 (1.41%). The company has increased its dividend annually over the past 5 years with an average increase of 5.37%, and maintains a sustainable 49% payout ratio. With solid earnings growth projected at 7.41% for 2026, JNJ is rated as a Hold (Zacks Rank #3), making it suitable for income-focused investors seeking stable cash flow from an established healthcare leader.
- Zacks Investment Research·Neutral
Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Johnson & Johnson stock declined 2.22% on September 8, 2026, underperforming the S&P 500's 0.58% loss. The company is expected to report earnings on October 13, 2026, with forecasted EPS of $2.95 (up 5.36% YoY) and revenue of $25.36 billion (up 5.71% YoY). JNJ holds a Zacks Rank #3 (Hold) rating with a Forward P/E of 23.75, trading at a premium to its industry average.
- GlobeNewswire Inc.·
NANOBIOTIX ANNONCE LA PRÉSENTATION DE DONNÉES DE LA PREMIÉRE PARTIE DE L’ÉTUDE CLINIQUE RANDOMISÉE DE PHASE 2 EVALUANT JNJ-1900 (NBTXR3) DANS LES CANCERS DU POUMON DE STADE 3 INOPÉRABLE
Nanobiotix announced early results from the Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer developed in collaboration with Johnson & Johnson, in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising efficacy with an 85.7% overall response rate and 57.1% complete response rate in 7 patients who completed treatment, compared to less than 5% complete response rates with current standard of care.
- GlobeNewswire Inc.·
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix announced promising Part 1 data from the CONVERGE Phase 2 study evaluating JNJ-1900 (NBTXR3), a nanoradioenhancer, in stage 3 inoperable non-small cell lung cancer. Results showed an 85.7% overall response rate and 57.1% complete response rate in 7 patients receiving the treatment combined with concurrent chemoradiotherapy and durvalumab, significantly exceeding the <5% complete response rate of standard care.
- Yahoo Finance·Neutral
Johnson & Johnson (JNJ): Growth Engine at a Value Price